Drug updated on 3/28/2024
| Dosage Form | Solution (oral: 2 mL) |
| Drug Class | Vaccines |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the prevention of rotavirus gastroenteritis caused by types G1, G2, G3, G4, and G9.
Summary
- The rotavirus vaccine, live, oral, pentavalent (RotaTeq) is indicated for the prevention of rotavirus gastroenteritis caused by types G1, G2, G3, G4 and G9.
- A total of 5 systematic reviews/meta-analyses were reviewed to gather information about RotaTeq's effectiveness in real-world settings.
- According to one study included in the review process, RotaTeq demonstrated an overall vaccine effectiveness estimate of 84% against RV infection particularly in high-income countries where socioeconomic status was found to have a significant impact on its efficacy.
- Another meta-analysis revealed that both Rotarix and RotaTeq significantly reduced RVGE and hospitalization risk among fully vaccinated children under five years old with no significant differences between their protection levels against rotavirus disease noted during adjusted indirect comparisons.
- In sub-Saharan Africa where over 34 countries have introduced either monovalent or pentavalent vaccines into their national immunization programs since South Africa did so in 2009; it was observed that introduction of these vaccines including RotaTeq has led to a significant reduction in burden associated with rotavirus-associated diarrhea especially among children less than twelve months old compared those aged between twelve and twenty-four months old according to another study.
- However despite demonstrating lower efficacy rates as well as more rapid waning effects within high-mortality settings when compared low-mortality ones based on findings from yet another study; live oral versions such as Rotarix or RotaTeq are still considered beneficial due earlier peak age diseases occurring within these regions which makes them likely candidates for providing substantial benefits even if they may not be optimal choices elsewhere given current evidence available regarding their performance across different mortality strata worldwide.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| RotaTeq (rotavirus vaccine, live, oral, pentavalent) Prescribing Informtion. | 2023 | Merck Sharp & Dohme LLC Rahway, NJ |